Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, share and growth analysis with key players Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc., Purdue Pharma L.P.,

According to a new report published by Allied Market Research, titled, " Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 20172023," the global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023.

Aneurysmal subarachnoid hemorrhage is a kind of stroke, which is caused by bleeding in the subarachnoid space of the brain. The major reasons for aneurysmal subarachnoid hemorrhage include brain aneurysm, arteriovenous malformation, or head injury. Change in lifestyles such as smoking and alcohol consumption increase the risk for aSAH, as well as rise in geriatric population are the major factors that contribute to the growth of the market. Moreover, increase in prevalence of hypertension, and stroke further boost the market growth. However, the associated side effects of the drugs are expected to impede the market growth. In addition, a need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage provide lucrative opportunities for the market growth.

Get sample copy of this report at:
https://www.alliedmarketresearch.com/request-sample/4602

Opioid analgesics generated the maximum revenue, accounting for more than two-fifths share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016. The calcium channel blockers segment is expected to witness the highest CAGR of 4.5% during the forecast period, owing to their ability to reduce the risk of brain damage.

Key Findings of the Aneurysmal Subarachnoid Hemorrhage Drugs Market:

• The opioid analgesics segment is expected to grow at a significant CAGR of 2.6% during the forecast period.

• The anticonvulsants segment contributed nearly one-fourth share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016.

• The stool softeners segment is projected to grow at a significant CAGR of 4.2% during the forecast period.

• Germany and France are the major shareholders, which collectively accounted for more than one-third share of the European aneurysmal subarachnoid hemorrhage drugs market in 2016.

• Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific aneurysmal subarachnoid hemorrhage drugs market in 2016.

Get customized copy of this report at:
https://www.alliedmarketresearch.com/request-for-customization/4602

The Asia-Pacific market is projected to grow at the highest CAGR of 5.5% during the forecast period, owing to rise in awareness about the treatment of aneurysmal subarachnoid hemorrhage in the healthcare industry and surge in expenditures in emerging markets (such as India and China) to cater to the unmet medical needs.

Key players in the market:

• Arbor Pharmaceuticals Inc.
• Edge Therapeutic Inc.
• Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
• Mylan N.V.
• Orexo AB
• Pfizer Inc.
• Purdue Pharma L.P.
• Pharmaxis Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)

Table of content:

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2016
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rising geriatric population
3.4.1.2. Increasing prevalence of stroke and hypertension
3.4.1.3. Lifestyle modifications which increase the risk of aSAH

3.4.2. Restraints

3.4.2.1. Side effects of the drugs

3.4.3. Opportunities

3.4.3.1. Need for growing awareness about the treatment of aSAH

3.4.4. Impact analyses

Access full summary at: https://www.alliedmarketresearch.com/aneurysmal-subarachnoid-hemorrhage-drugs-market

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Deep joshi
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.